SwanBio Therapeutics Announces Series A Expansion to Fund its Lead Program and Grow Pipeline in Gene Therapy for Neurological Diseases
Apr 23, 2020•about 5 years ago
Round Type
series a
Description
SwanBio Therapeutics, a gene therapy company developing leading-edge medicines to deliver dramatic clinical efficacy for the treatment of AMN and other neurological diseases, today announces the successful completion of a $52 million expanded Series A financing.
FundzWatch™ Score
70
Medium Activity
Buyer Intent Analysis
Get personalized insights on buying likelihood